Showing 20 of 28 recruiting trials for “obsolete-inherited-predisposition-to-essential-thrombocythemia”
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingNCT06976918 ↗
Registry Platform Myelofibrosis and Anemia
👨⚕️ Konstanze Döhner, Prof. Dr. med., University Hospital Ulm, Germany📍 1 site📅 Started Feb 2026View details ↗
RecruitingNCT07203768 ↗
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
👨⚕️ TIZIANO BARBUI, MD, FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS📍 25 sites📅 Started Dec 2025View details ↗
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Efficacy and Safety of Peginterferon in ET and PV.
👨⚕️ ZhenYa Hong, Ph.D, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Nov 2024View details ↗
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
👨⚕️ John Mascarenhas, Icahn School of Medicine at Mount Sinai📍 1 site📅 Started Oct 2024View details ↗
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
👨⚕️ Casey L O'Connell, MD, University of Southern California📍 2 sites📅 Started Mar 2024View details ↗
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
👨⚕️ Marina Kremyanskaya, PhD, MD, Icahn School of Medicine at Mount Sinai📍 9 sites📅 Started Jul 2023View details ↗
RecruitingNCT06073847 ↗
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
RecruitingNCT05440838 ↗
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
RecruitingNCT05882773 ↗
Asian Myeloproliferative Neoplasm (MPN) Registry
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
👨⚕️ Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai📍 1 site📅 Started Apr 2023View details ↗
Study of Canakinumab in Patients With Myelofibrosis
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →